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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not there
is a mortality benefit with the use of aspirin in the primary prevention setting in adults without
cardiovascular disease.
STUDY DESIGN: This is a systematic review of three double blind randomized controlled
trials published in 2018. All three trials compared 100 mg of aspirin with placebo and were
published in English.
DATA SOURCES: All three articles were identified and published through peer-reviewed
sources using PubMed.
OUTCOMES MEASURED: Mortality was the outcome measured through various death
identification steps such as review of death certificates, notification from next of kin, and review
of medical records.
RESULTS: The ASPREE trial showed that aspirin was associated with an increase in all-cause
mortality. There was 5.9% mortality in the aspirin group versus 5.2% in the placebo group with
statistically significant results (p-value < 0.05) (McNeil JJ, Nelson MR, Woods RL, et al. N Engl
J Med. 2018;379(16):1519-1528. doi: 10.1056/NEJMoa1803955 [doi]). The ARRIVE trial
showed that participants taking aspirin had a 1% reduced risk of mortality compared to those
taking the placebo (hazard ratio = 0.99) (Gaziano JM, Brotons C, Coppolecchia R, et al. Lancet.
2018;392(10152):1036-1046. doi: S0140-6736(18)31924-X [pii]). However, the results were not
statistically significant with a p-value > 0.05. The ASCEND trial showed that those taking
aspirin have a reduced risk of death compared to those taking the placebo (rate ratio = 0.94)
(Bowman L, Mafham M, Wallendszus K, et al. N Engl J Med. 2018;379(16):1529-1539. doi:
10.1056/NEJMoa1804988 [doi]). These results were not statistically significant (p-value > 0.05).
CONCLUSIONS: The data did not show that the use of aspirin in the primary prevention
setting has a mortality benefit in adults without cardiovascular disease. ASPREE was the only
trial that had statistically significant results and it showed a higher rate of mortality in those
taking aspirin. ASCEND and ARRIVE trials showed a small mortality benefit in those taking
aspirin. However, these findings were not statistically significant. These compelling findings
need to be investigated further with large scale studies using mortality as a primary investigative
endpoint.
KEY WORDS: Aspirin, Primary Prevention, Cardiovascular Disease
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INTRODUCTION
Cardiovascular disease (CVD) is a term that encompasses a collection of disorders that
involve the heart and blood vessels such as coronary artery disease, peripheral vascular disease,
and cerebrovascular disease. Globally, CVD is the leading cause of death among adults from
clinical events such as acute myocardial infarction and cerebrovascular accident.1 Primary
prevention is a term used to describe actions and efforts aimed at avoiding a specific disease. In
other words, primary prevention is aimed at preventing a disease from manifesting in an
otherwise healthy individual. Secondary prevention is a term used to describe actions and efforts
aimed at lessening the severity or slowing the progression of a disease that has already
manifested. The usual methods of primary and secondary prevention of CVD include diet,
exercise, avoidance of tobacco, and controlling comorbidities such as dyslipidemia, diabetes
mellitus (DM), and hypertension. What makes these preventative measures primary or secondary
is whether or not an individual has developed the disease.
Aspirin use as a primary prevention measure is extremely common, despite the absence
of strong evidence. Millions of individuals report taking aspirin as a primary prevention strategy,
without a known history CVD, according to data from the 2017 National Health Interview
Survey (NHIS).2 The majority of these individuals were doing so without instruction from their
physician.2 Public fear of CVD is warranted with staggering statistics on costs, hospitalizations,
and long term disabilities. The healthcare costs involved with long-term care and the acute phase
of CVD are substantial. It is estimated that $329.7 billion is spent each year in the US on CVD.3
It is projected that CVD will cost $749 billion in the year 2035.3 In 2016, 2.2 million people
were hospitalized for stroke, myocardial infarction, and heart failure.4
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A meta-analysis of RCTs by the Antithrombotic Trialists’ Collaboration has shown an
irrefutable benefit of long-term aspirin use as secondary prevention in patients with known
CVD.5 That strategy is fundamental in the established guidelines in the American College of
Cardiology regarding treatment of patients with established disease. The use of aspirin, having
antithrombotic effects by inhibiting platelet function, involves an increased risk of bleeding. It is
unclear whether or not the use of aspirin in the primary prevention setting in adults without
cardiovascular disease is beneficial enough to outweigh the known bleeding risk. This paper
evaluates three RCTs comparing the effects of aspirin in the primary prevention setting in adults
without CVD. Specifically, this systematic review has a primary focus of examining effects on
mortality.
OBJECTIVE
The objective of this selective evidence-based medicine review is to determine whether
or not there is a mortality benefit with the use of aspirin in the primary prevention setting in
adults without cardiovascular disease.
METHODS
This systematic review utilized three randomized, double-blind, placebo-controlled trials.
All articles were published in peer-reviewed journals. They were selected based on relevance to
the clinical question and chosen on the basis that the outcomes of the studies mattered to
patients, POEMs (Patient-Oriented Evidence that Matters). PubMed was used to identify
appropriate articles using the key words, “aspirin,” “primary prevention,” and “cardiovascular
disease.” Studies were considered if they were published within the last 10 years from the date of
the search strategy (2008-2018). However, all three articles selected were published in 2018.
Exclusion criteria included children, adolescents, adults younger than 40, and data published
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before 2008. See table 1 for the inclusion and exclusion criteria utilized by the investigators of
each study that was included in this systematic review.
In order to best answer the clinical question, specific criteria were used to narrow down
selection of studies. The population considered was adults without cardiovascular disease older
than 40 years old. Each RCT had slightly unique population criteria. The ASPREE population
was adults ≥ 70 or ≥ 65 among blacks and Hispanics. The ASCEND trial included individuals ≥
40 years old with DM but no evidence of CVD. The ARRIVE trial focused on men 55 and older
and women 60 years and older who had an average cardiovascular risk (between two and four
risks factors for men and three or more for women). The risks factors included current smoking
(any in the last 12 months), low HDL cholesterol (< 40 mg/dL), high blood pressure (systolic >
140 mmHg), receiving medication to treat high blood pressure, positive family history of
cardiovascular heart disease, high cholesterol (total cholesterol > 200 mg/dL or LDL > 130
mg/dL for men; total cholesterol > 240 mg/dL or LDL > 160 mg/dL for women). The
intervention was 100 mg of enteric-coated aspirin. The treatment group receiving aspirin was
compared to the group who received placebo. This systematic review focuses specifically on the
outcome of mortality.
The statistic methodology analyzed by each study differed slightly. The number needed
to harm (NNH) was calculated for each RCT and all three included 95% confidence intervals
(CI). ARRIVE and ASPREE reported p-values and hazard ratios. ASCEND used a rate ratio.
OUTCOMES MEASURED
The outcome measured for this systematic review was mortality. Mortality was measured
by various methods of death identification. In the ASPREE trial, death was identified when
failure to attain contact with participants occurred.6 Investigators reviewed health records, death
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Table 1. Demographics & Characteristics of Included Studies
Study

Type

# Pts

Age (yrs)

ASPREE6
(2018)

Double
Blind
RCT

19,114

≥ 70 or ≥ 65
among blacks
and Hispanics

ASCEND7
(2018)

Double
Blind
RCT

15,
480

≥ 40 years old

ARRIVE8
(2018)

Double
Blind
RCT

12,546

55 years (men)
or 60 years
(women) and
older who had
an average
cardiovascular
risk (10-year
risk of CHD of
10-20%)

Inclusion
Criteria
Do not have
cardiovascular
disease,
dementia, or
disability
from
Australia and
the US
Men and
women at
least 40 years
old who have
DM, but no
evidence of
CVD

Between two
and four risk
factors for
men and three
or more risk
factors for
women; no
previous
history of
CVD

Exclusion
Criteria
Younger than
70 or younger
than 65 if black
or Hispanic; hx
of CVD,
dementia, or
disability

W/D

Interventions

257
(aspirin
group)
and 276
(placebo
group)

Entericcoated aspirin
(100 mg)

Clear indication
for aspirin or a
contraindication
to aspirin or the
presence of
other clinically
significant
conditions that
might limit
adherence to
the trial
regimen for at
least 5 years
Hx of vascular
event (stroke,
MI, coronary
artery
angioplasty or
stenting),
CABG, relevant
arrhythmias,
CHF, diabetes,
patients
requiring
antiplatelet
therapy, history
of GI bleeding,
those using
anticoagulants
or frequent use
of NSAIDs,
those with
vascular
intervention

69
(aspirin
group)
and 70
(placebo
group)

Entericcoated aspirin
(100 mg)

1843
(aspirin)
and 1875
(placebo)

Entericcoated aspirin
(100 mg)

notices, and obituaries.6 Sometimes family members would notify the trial investigators. Two
independent sources were required for death identification such as from family members,
primary care physicians, or public death notices.6 In the ARRIVE trial, participants would
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undergo follow-up from primary care physicians during face-to-face meetings, over the phone,
and through medical record reviews.8 The ASCEND trial death identification involved methods
similar to both ARRIVE and ASPREE with the use of adjudication and review of death
certificates and information about events prior to the death.7
RESULTS
This selective EBM used three RCTs to determine whether there is a mortality benefit
with the use of aspirin in adults without cardiovascular disease. All three studies were doubleblind, randomized controlled trials. To avoid bias, neither the participants nor the researchers
knew who was receiving aspirin or placebo. Each study used a slightly unique population, as
seen in table 1. However, all participants were adults over 40 years old without a history of
cardiovascular disease.
The ASPREE trial, which stands for the “Aspirin in Reducing Events in the Elderly,”
focused on people who were 70 years old or older (or ≥ 65 years of age for blacks and
Hispanics).6 The trial included people from the United States and Australia. Recruitment in
Australia was primarily through the participant’s primary care physician.6 Recruitment in the
United States was primarily done through the community via academic health centers.6 The total
number of participants in the ASPREE trial was 19,114; the group who received aspirin had
9,525 people and the group who received placebo had 9,589 people.6 In the aspirin group, 139
participants were lost to follow-up and 118 withdrew consent.6 In the placebo group, 157
participants were lost to follow-up and 119 withdrew their consent.6 Over a median of 4.7 years,
a total of 1,052 deaths occurred.6 There was 5.9% all-cause mortality in the aspirin group and
5.2% in the placebo group (p-value = 0.03).6 Statistical analysis showed a hazard ratio of 1.14
(95% CI: 1.01-1.29).6 This can be interpreted as the aspirin group had a 14% increased risk of
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mortality as compared to placebo. The number needed to harm (NNH) was 141. These results
were statistically significant.
Table 2. All-cause mortality statistics in the ASPREE trial
Study

NNH

Hazard Ratio

ASPREE

141

1.14

Confidence
Interval (CI)
1.01-1.29

P-value
0.03

The ARRIVE trial, which stands for “Aspirin to Reduce Risk of Initial Vascular Events,”
had a patient population of patients aged 55 years (men) or 60 years (women) and older who had
an average cardiovascular risk.8 Further details of cardiovascular risk details, inclusion, and
exclusion criteria can be found in the methods section of this paper. The study involved patients
from Germany, Italy, Poland, Ireland, Spain, the UK, and the USA in the setting of a primary
care office. The total number of participants was 12,546.8 They were randomly assigned to
receive aspirin (6,270 participants) or placebo (6,276).8 Over the course of approximately 6
years, participants had 9 visits with their primary care provider and key variables were recorded.8
In the aspirin group, 1,843 participants withdrew from the study.8 In the placebo group, 1,875
withdrew.8 There were 277 deaths during the length of the trial.8 Statistical analysis showed a
hazard ratio of 0.99 with a 95% confidence interval of 0.80-1.24.8 The p-value was 0.9459.8 This
can be interpreted as those taking aspirin have a 1% reduced risk of mortality compared to those
taking placebo. However, these results were not statistically significant.
Table 3. All-cause mortality statistics from the ARRIVE trial
Study

NNH

Hazard ratio

ARRIVE

5,000

0.99

Confidence
Interval (CI)
0.80-1.24

P-value
0.9459
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The ASCEND trial, which stands for “A Study of Collaborative Events iN Diabetes,”
focused on adults over 40 years old with diabetes, but no manifestations of cardiovascular
disease.7 Recruitment was done using regional diabetes registers or primary care offices in the
United Kingdom.7 All types of diabetes were included.7 Confirmed participants were sent a 6
month supply of 100 mg of aspirin or a matching placebo pill, as well as 1 gram capsules of
omega-3 fatty acid or a matching placebo capsule.7 Therefore, ASCEND had a 2x2 factorial
blinded design.7 All pills and capsules were to be taken once daily.7 These supplies and a
questionnaire were sent every 6 months during the trial.7 For the purpose of this systematic
review, data were focused on aspirin versus placebo. The questionnaires recorded information
such as serious adverse events, trial regimen adherence, use of other antiplatelet or
anticoagulation, events causing discontinuation of the trial procedure, and any symptomatic
bleeding episodes that caused the patients to seek medical attention.7 A total of 15,480
participants were randomized; 7,740 patients in each group.7 Participants were followed for a
mean follow-up period of 7.4 years.7 There was a total of 1,540 deaths during the trial.7 A total
of 69 participants in the aspirin group and 70 participants in the placebo group yielded
incomplete follow-up information at the culmination of the trial.7 Reasons for incomplete followup information include withdrawal of consent, participants moving abroad, and death.7 748
deaths occurred in the aspirin group and 792 deaths in the placebo group.7 The statistical analysis
showed that participants taking the aspirin had 0.94 times risk of mortality, using a rate ratio.7 In
other words, they had a slightly decreased risk of mortality compared to the participants taking
placebo. The confidence interval was 0.85-1.04.7 Therefore, the result of aspirin decreasing risk
of mortality was not statistically significant (p-value > 0.05).
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Table 4. All-cause mortality statistics from the ASCEND trial
Study

NNH

Rate ratio

ASCEND

175

0.94

Confidence
Interval (CI)
0.85-1.04

P-value
> 0.05

DISCUSSION
Cardiovascular disease is one of the major causes of morbidity and mortality worldwide.
In the US, one out of every three deaths is from CVD and it causes more deaths than cancer and
chronic pulmonary diseases combined.3 Given the solid evidence for the use of aspirin in
individuals who have already had a cardiovascular event, it is plausible to propose that there may
be benefit for people in the primary prevention setting in an attempt to avoid cardiovascular
events and prevent premature mortality. Unfortunately, aspirin is not void of risks. Aspirin is an
antiplatelet medication, thinning the blood and making it easier to have bleeding complications.
Additionally, there is risk of an allergic reaction or drug interactions.
The three randomized control trials showed no statistically significant mortality benefit in
the use of aspirin in the primary prevention strategy. Moreover, ASPREE had statistically
significant results that those taking aspirin had a higher all-cause mortality than the participants
assigned to take placebo. This higher all-cause mortality was attributed to cancer.6 There was no
clear tie to a specific type of cancer or tumor location.6 However, the broad category of
gastrointestinal cancer was a large contributor to cancer-related mortality.6 Of note, ASPREE
had the oldest participant population. Advancing age is the number one risk factor in the
development of various individual cancer types.9 Therefore, the relationship between an older
patient population and the leading cause of cancer-related deaths as the major cause of mortality
is a possible limitation to this study. Additionally, there was a statistically significant rate of
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hemorrhage in the aspirin group compared to placebo with a hazard ratio of 1.38 (95% CI: 1.181.62; p-value < 0.001).6 The strengths of this study include the large sample size, randomized
and blinded study design, and ease of access to clinical records, which allowed the investigators
to obtain accurate and complete information. Other limitations include the relatively short
follow-up period and specific age range of participants, limiting the statistical power of the
results and ability to generalize to the broader U.S. population.
The ARRIVE trial did not demonstrate a statistically significant reduction in mortality
using a primary prevention aspirin strategy. It found a small, insignificant reduction of mortality
in adults with average risk of CVD (10-year risk of 10-20%) who took aspirin. Of note, there
was a statistically significant risk of gastrointestinal bleeding in the aspirin group (p-value =
0.0007).8 ARRIVE had participants from seven countries, including the US, making the data the
most generalizable out of the three RCTs. Other strengths include the large sample size,
randomized and blinded study design, and the practicality of the primary care setting. During the
study, there was public media discussion on the uncertainty of aspirin in the primary prevention
setting in the UK.8 The results from the UK reflected a difference compared to the other
countries including a high rate of withdrawal from the study.8 This is a limitation to the ARRIVE
trial. Other limitations include identifying a population with true moderate risk of CVD and
compliance.
The ASCEND trial also did not show a statically significant reduction in mortality in the
aspirin group compared to placebo. Like the ARRIVE trial, the rate of major hemorrhagic
bleeding events was statistically significantly higher in the aspirin group (p-value = 0.003).7
Strengths of the study include the randomized and blinded study design, large sample size, and
nearly complete follow-up information. ASCEND had its own limitations. It was a trial
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completed only in the UK, narrowing the generalizability. The patient population was individuals
with all types of diabetes, a specific group of patients that often have high rates of comorbidities
and complications from their disease. Another limitation is that there was speculation that there
was an association of diabetes and reduced efficacy of aspirin.7 However, the study did not
appear to support this.7 In addition to aspirin, participants were randomized to take omega-3 fatty
acid capsules or a placebo, which could be a confounding variable.
CONCLUSIONS
Is there a mortality benefit with the use of aspirin in the primary prevention setting in
adults without cardiovascular disease? According to the data from this systematic review of three
randomized, double-blind, placebo-controlled trials, the answer to this clinical question is no.
The lack of a mortality benefit utilizing aspirin in a primary prevention strategy was consistent
across these three trials. The only statistically significant results were from the ASPREE trial and
the data was on the contrary. The use of aspirin was associated with a higher rate of all-cause
mortality. Inherent potential limitations were identified in all three trials. However, the totality of
the patient populations yielding the same conclusion is compelling. Consistently, a statistically
significant increased risk of bleeding in patients on aspirin was identified in all three trials. In
conclusion, the evidence to support the use of aspirin to lower an individual’s mortality risk is
not supported by the three aforementioned trials. The specific patient population of adults at high
risk for developing CVD, but without CVD, was not included in these three RCTs. Therefore,
the decision to incorporate aspirin into a patient’s daily regimen should be an individual choice,
unique to each patient’s cardiovascular risk. It should be a collaborative decision between the
individual and their healthcare provider. Consistent with standard medical practice, the risks and
benefits must always be weighed. Decisions should be based upon evidence-based,

Bernardi, Aspirin & Mortality 11
contemporary data. To definitively answer this clinical question, it will likely require ongoing
large, diverse, and long-term studies perhaps focusing on specific high risk and low risk groups
of patients.
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